Maravai LifeSciences Holdings, Inc.
HealthcareNASDAQ:MRVI · NASDAQ Global Select
-$0.23 today
Vol 1.66M · Avg 2.44M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$204.7M of revenue converted into -$104.6M of net income for the selected period. Gross margin is 26.4% and net margin is -55.5%, showing how much revenue survives after costs and taxes. EPS is $-0.73, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $185.7M -28.3% | $259.2M -10.3% | $288.9M -67.3% | $883.0M +10.5% | $799.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $152.4M +1.0% | $150.9M +1.4% | $148.7M -12.0% | $169.0M +20.2% | $140.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $33.4M -69.2% | $108.3M -22.7% | $140.2M -80.4% | $714.0M +8.4% | $658.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 18.0% -23.8pp | 41.8% -6.7pp | 48.5% -32.3pp | 80.9% -1.5pp | 82.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $23.3M +21.4% | $19.2M +11.2% | $17.3M -5.9% | $18.4M +20.7% | $15.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $171.5M +6.0% | $161.8M +6.9% | $151.4M +17.1% | $129.3M +29.2% | $100.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $40.1M -88.3% | $343.9M +100.1% | $171.8M +22.9% | $139.8M +34.4% | $104.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $60.9M +7.0% | $56.9M +16.6% | $48.8M +28.0% | $38.1M +53.9% | $24.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$147.1M +6.2% | -$156.9M -122.0% | $712.4M +16.8% | $610.0M +4.1% | $585.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -79.2% -18.7pp | -60.5% -307.1pp | 246.6% +177.5pp | 69.1% -4.2pp | 73.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$6.7M +97.1% | -$235.6M -644.5% | -$31.6M -105.5% | $574.2M +3.5% | $554.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -3.6% +87.3pp | -90.9% -80.0pp | -11.0% -76.0pp | 65.0% -4.4pp | 69.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $23.9M -12.6% | $27.4M -1.2% | $27.7M +1085.9% | $2.3M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $27.0M -43.4% | $47.7M +3.9% | $45.9M +124.8% | $20.4M -32.5% | $30.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$228.2M -782.4% | -$25.9M -104.0% | $649.4M +2955.2% | -$22.7M +4.8% | -$23.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$235.0M +10.1% | -$261.5M -142.3% | $617.7M +12.0% | $551.5M +3.9% | $530.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -126.5% -25.6pp | -100.9% -314.7pp | 213.8% +151.3pp | 62.5% -4.0pp | 66.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$4.2M -126.5% | -$1.9M -100.2% | $756.1M +1143.4% | $60.8M -1.1% | $61.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$130.8M +9.7% | -$144.8M -21.7% | -$119.0M -154.1% | $220.2M +21.0% | $182.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -70.4% -14.5pp | -55.9% -14.7pp | -41.2% -66.1pp | 24.9% +2.2pp | 22.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +13.3% | -$1 -16.7% | -$1 -153.9% | $2 +5.0% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +13.3% | -$1 -16.7% | -$1 -153.9% | $2 +7.1% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $145.1M +5.2% | $137.9M +4.5% | $131.9M +0.3% | $131.5M +14.6% | $114.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $145.1M +5.2% | $137.9M +4.5% | $131.9M +0.2% | $131.7M +8.0% | $122.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Septerna, Inc.
NASDAQ:SEPN
$1.62B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$212.27M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MRVI generate?
Maravai LifeSciences Holdings, Inc. (MRVI) reported $185.74M of revenue in fiscal 2025.
Is MRVI profitable?
Maravai LifeSciences Holdings, Inc. (MRVI) reported -$130,773,000.00 of net income, with a net margin of -70.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.